1. Whys

 

Pneumonovax 23 is a vaccine designed to prevent pneumococcal infections, such as pneumonia, meningitis, and bacteremia, caused by 23 different strains of streptococcus pneumonia bacteria. This PFS(pre-filled syringe) is a convenient, sterile ,ready to use liquid format for administration.

Pneumonovax 23 is a vital vaccine that protects against 23 strains of streptococcus pneumonia bacteria, which cause severe,sometimes fatal infections like pneumonia, meningitis, and bloodstream infections. It is critical for adults 65 plus ,smokers ,and individuals with chronic hospitalization and severe infections.

 

HOW IMPORTANT DOES PNEUMNOVAX 23 PFS VACCINE FOR ADULTS?

Pneumonovax 23 (PPSV23) is a crucial vaccine for adults aged 50 plus and those with high -risk conditions, protecting against 23 types of pneumonia causing bacteria. It significantly reduces the risk of invasive pneumococcal disease and pneumonia ,lowering hospitalization and morality ,particularly in older adults and individuals with degenerative illness.

 

Target group: recommended for adults 65 plus ,adults 19-64 with chronic conditions (e.g asthma, COPD,diabetes, heart disease) ,smokers and immune compromised individuals.

Protection: covers 23 common streptococcus pneumonia e stereotypes responsible for over 90% of invasive disease.

Administration: typically a single intramuscular injection ,with a booster sometimes recommended after 5 years for high-risk individuals

Effectiveness: studies indicate an overall efficacy of 60-70% in preventing invasive disease.

Side effects: common reactions include soreness at the injection site, fever or rash.

 

WHAT IS PNEUMNOVAX 23?

Pneumococcal polysachride  vaccine, sold under the brand name pneumnovax 23 ,is a pneumnococal vaccine that is used for the prevention of pneumococcal disease caused by the 23 stereotype of streptococcus pneumoniae contained in the vaccine as capsular polysachrides.  The polysachrides agents were added to induce type-specific antibodies that enhance phagocytes and killing of streptococcus pneumonia e bacteria by phagocyte immune cells.

Pneumovax 23 is manufactured by Merck sharp &Dohme corp..,a subsidiary of Merck &co ,inc . it is a vaccine designed to protect against infections caused by streptococcus  pneumoniae bacteria , including pneumonia and meningitis. The product is often distributed as a pre -filled syringe .

Key manufacture & Information

Manufacturer: Merck Sharp & Dohme corp. 

Alternative name: Merck Sharp & Dhome BV (often used in international contexts) .

Manufacturing site: west point ,Pennsylvania,USA

Distributor/Marketer :  MSD pharmaceuticals pvt ltd. (india)

Format: As of April 2023, the manufacturer supplies PNUMOVAX 23 primarily as a 10-pack of pre -filled single-dose Luer -lok syringes.

The vaccine is indicated for individuals 2 years of age and older, with a focus on adults 50 and older or those with high risk conditions.

 

WHAT DISEASES DOES PNEUMONOVAX 23 PREVENT?

Diseases that are prevented by PNEMONOVAX 23 are :

PNEUMONOCOCAL PNEUMONIA

Pneumnovax 23 (PPSV23) helps prevent pneumococcal pneumonia and other serious infections caused by 23 common strains of streptococcus pneumonia bacteria.it is highly recommended by adults up to 65 age, individuals aged 2 plus with high -risk conditions and smokers. It protects against 23 strains of bacteria, reducing the risk of severe disease and hospitalization. it is effective at preventing pneumococcal pneumonia, particularly in reducing morality for high-risk individuals and nursing home residents.

 

BACTEREMIA (BLOODSTREAM INFECTION) 

Pneumococcal vaccines (PCV13, PPSV23) are highly pneumococcal disease, including bacteremia, (bloodstream infection ) and pneumococcal pneumonia ,by inducing antibodies that target specific stereotypes of streptococcus pneumoniae.  Studies shown that vaccines can be 78.5% effective in preventing type-specific pneumococcal pneumonia and bacteremia.  It works by stimulating antibodies that block the bacteria from invading the blood or causing pneumonia.

MENINGITIS

Pneumonia l cocal vaccines (PCV13, PCV15, PCV20 and PCV23) are the primary, highly effective method to prevent both pneumococcal meningitis and pneumococcal pneumonia. These vaccines protect against various strains of streptococcus pneumonia  bacteria that can cause both invasive diseases . these vaccines target the most common harmful strain . since the year  2000 , these vaccines have saved over 1.6 million lives and significantly reduce the incidence of morality  from pneumococcal disease.

 

OTHER INVASIVE PNEUMOCOCCAL DISEASES

Invasive pneumococcal diseases (IPD) including bacteria , septicemia and meningitis- are severe infections caused by streptococcus pneumonia that are effectively prevented by pneumococcal conjugate vaccines (PCV13, PCV15, PCV20) and the polysachride vaccine (PPSV23) ,which also protect against pneumococcal pneumonia .it reduces the overall burden of disease.

 

HOW IS PNEUMNOVAX 23 ADMINISTERED?

Pneumnovax works by each integrating the immune system to produce antibodies against 23 common types of streptococcus pneumoniae bacteria, protecting against invasive diseases like pneumonia and meningitis. It is a  polysachride vaccine that uses purified sugar coatings from the bacteria to trigger an immune response without causing disease.

Pneumnovax 23 administrated by the following ways:

STIMULATE  IMMUNE RESPONSE

Pneumonovx 23 (PPSV23) stimulate the immune response by exposing it to 23 different purified capsular polysaccharide antigens from the most common and invasive streptococcus pneumonia  bacteria. It is designed to trigger a T-cell-independent immune response .primarily in adults aged 50 and other high risk individuals.

 

PRODUCTION  OF PROTECTIVE ANTIBODIES

Pneumonovax 23 (PPSV23) is a 23- variant pneumococcal polysachride vaccine designed to induce type-specific antibodies that heighten optimization ,phagocytes . proactive antibody levels generally develop within 2 to 3 weeks after vaccination. More than 80% of healthy adults develop antibodies against the stereotype in the vaccine . studies show a 5.4 -fold average increase in antibody levels across different stereotypes.  The vaccine is 60% to 70% effective in preventing invasive pneumococcal disease (IPD) in healthy adults.

 

WHAT ARE THE  POSSIBLE SIDE EFFECTS OF PNEUMNOVAX 23 ?

Pneumounovax 23 commonly causes mild, short term side effects ,primarily injection site reactions  like pain, swelling and redness , which may occur in over 75% of patients . other common side effects include headache, fatigue ,muscle pain ,fever and reduced appetite ,generally resolving within 1-2 days.

 

Common side effects:

Injection site reactions: pain/soreness /tenderness (60%-70%) ,swelling/induration (20%-40%) and redness (16%-35%)

Systematic reactions: headache (17%-18%),fatigue /asthenia(13%-18%)

General:  fever (less than 10%)

 

Less common side effects

Local: intense swelling,  ‘’cellulitis-like’’ reactions or hard lumps at the injection site.

Systematic: chills, joint pain ,nausea ,vomiting or rash

Rare :severe allergic reactions or in very cases, Guillain- Barre syndrome.

 

CONCLUSION: pneumonovax 23 (PPSV23) is a highly effective ,safe vaccine for preventing invasive pneumococcal disease (IPD) caused by 23 stereotypes in adults >65 and high-risk individuals . it offers moderate protection against pneumonia and reduces hospitalization ,though its effectiveness may decrease with age and it is not recommended for children under 2.

 

FREQUENTLY ASKED QUESTIONS: 

QUESTION:  HOW LONG DOES PNEUMONOVAX 23  PROTECTION LAST?

Pneumnovax 23 typically provides protection for about 4 to 7 years in adults with antibody levels decline afterward . while some protection may last longer, a booster is often recommended every 5 years for high-risk individuals. Protection begins 2 to 3 weeks after vaccination .

QUESTION: CAN PNEUMNOVAX 23 PREVENT VIRAL PNEUMONIA?

Pneumnovax does not directly prevent viral pneumonia .it specifically protects against 23 types of bacteria that cause bacterial pneumonia, meningitis and bloodstream infections. It is primarily used for adults 65 plus and high -risk individuals . however it can prevent secondary bacterial infections that often occur after a viral infection.

QUESTION: CAN PNEUMNOVAX 23 IS MANDATORY FOR ELDERLY INDIVIDUALS ?

Pneumnovax 23 is strongly recommended for all adults aged 65 years and older by major health organizations , including centre for disease control and prevention (CDC) . it is consider a crucial preventive health measure for elderly people to protect severe infections caused by streptococcus pneumococci bacteria , such as pneumonia, meningitis and bloodstream infections.

REFRENCES

1. https://www.nhs.uk/vaccinations/pneumococcal-vaccine/

2.https://www.apollopharmacy.in/medicine/pneumovax-vaccines-23-0-5ml?srsltid=AfmBOopP0KfiHXcID6lvvhdwPqAeeOvCAqlEGq4Lcdksx4_yOqO-HWIU

3.https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html

4.https://www.news-medical.net/drugs/Pneumovax-23.aspx